Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immutep Limited - American Depositary Shares (NQ:IMMP)

1.700 +0.010 (+0.59%)
Streaming Delayed Price Updated: 2:24 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immutep Limited - American Depositary Shares

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting
 
Via Benzinga
Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know
 
Via Benzinga
Unusual volume stocks in Wednesday's session
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
In today's session, these stocks are experiencing unusual volume.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy. 
Via Benzinga
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
 
Via Benzinga
Topics Stocks
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday 
Via InvestorPlace
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer... 
Via Benzinga
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
From Immutep Limited
Via GlobeNewswire
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall... 
Via Benzinga
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
From Immutep Limited
Via GlobeNewswire
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
7 Stocks That Could Triple Your Money by 2024
If you want to get well ahead of the market and don’t mind the risk factor, check out these stocks to triple your money. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
 
Via Benzinga
3 Best Penny Stocks Under $3 to Buy in June
If you don’t mind the immense risks associated with high-potential opportunities, these best penny stocks under $3 could be for you. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.